Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the maintenance of mild to moderate ulcerative
colitis remission with six months of treatment with 1.5 grams of mesalamine pellets each day
versus placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.